Mauna Kea Technologies Stock Performance and Recent Corporate Developments
Market Activity
- Stock Symbol: ALMKT.PA
- Closing Price: EUR 0.11 (down 2.88 % during the 24‑hour period ending 02:03 PM Central Europe on Wednesday 21 Oct 2026).
- Volume Traded: Approximately EUR 32 000 worth of shares.
- Total Shares Outstanding: 195.3 million.
- Market Capitalisation: EUR 20.9 million.
- Price Trend Since Last Month End: Down 27.9 %.
- Simple Moving Average (200 days): EUR 0.16.
- 52‑Week High: EUR 0.23 (13 Mar 2026).
- 52‑Week Low: EUR 0.07 (29 Dec 2025).
Recent Corporate Performance
Mauna Kea Technologies reported a strong nine‑month performance in 2026, driven by expanding global reach and a reinforced presence in the United States. Key highlights include:
- Sales Growth – Sales increased in line with the company’s strategic focus on new markets in Europe and beyond, with significant growth in probe volumes.
- United States Market – Pricing discipline and a broader customer base led to higher average selling prices and reduced discounts. Recent staffing enhancements have restored full coverage across all territories.
- Strategic Partnerships – The partnership with TaeWoong Medical entered an execution phase, adding a dedicated team to pursue high‑value U.S. accounts.
- Product Pipeline – A robust pipeline for the final quarter is driven by pancreatic lesion indications, system renewals, and additional partnership opportunities.
- Financial Position – The company remains well‑positioned, with resources projected to support operations through the end of 2027.
Comparable Stock Performance (Last 24 Hours)
| Company | Symbol | % Move | Current Price (EUR) | Market Capitalisation (EUR mn) |
|---|---|---|---|---|
| Ikonisys | ALICO.PA | –1.4 % | 1.41 | 22.7 |
| Nsc Groupe | ALNSC.PA | –3.33 % | 58 | 24.2 |
| Cogra | ALCOG.PA | +3.17 % | 6.48 | 22.4 |
| Graines Voltz | GRVO.PA | –3.85 % | 15.05 | 22 |
| Implanet | ALIMP.PA | –0.91 % | 0.15 | 21.6 |
(Note: Graines Voltz’s price‑to‑earnings ratio is 20.33.)
Company Overview
Mauna Kea Technologies SA is a Paris‑based medical device company founded in 2000. The firm specializes in designing, developing, and marketing endomicroscopy and optical biopsy tools for global disease diagnosis and treatment. Its flagship product, Cellvizio, is a confocal miniprobe endomicroscopy system that delivers high‑resolution cellular images to clinicians and researchers.
For further information on the company’s products and initiatives, visit the official website at www.maunakeatech.com . Shares are listed on NYSE Euronext Paris.